Tonegutti M, Girardi V
Servizio di Radiosenologia, Casa di Cura P. Pederzoli, Via Monte Baldo 19, 37019, Peschiera del Garda, Verona, Italy.
Radiol Med. 2008 Feb;113(1):65-75. doi: 10.1007/s11547-008-0226-0. Epub 2008 Feb 25.
We evaluated the reliability of stereotactic vacuum-assisted breast biopsies (VAB) from our personal experience.
Between January 2003 and December 2005, 268 patients underwent VAB with an 11-gauge probe at our institution. Inclusion criteria were nonpalpable lesions, undetectable by ultrasound and suspected at mammography (microcalcifications, circumscribed mass, architectural distortion), for which cytology and/or core biopsy could not provide a definite diagnosis. Lesion mammographic patterns were microcalcifications in 186 cases (77.5%), mostly localised clusters (130/186: 70%); circumscribed mass with or without microcalcifications in 36 cases (15%) and architectural distortion with or without microcalcifications in 18 cases (7.5%). On the basis of the Breast Imaging Reporting and Data System (BI-RADS) classification, 16 cases (7%) were graded as highly suspicious for malignancy (BI-RADS 5), 81 (34%) as suspicious for malignancy (BI-RADS 4b), 97 (40%) as indeterminate (BI-RADS 4a) and 46 (19%) as probably benign (BI-RADS 3). Lesion size was <or=10 mm in 161 cases (67%) and >20 mm in only 38 cases (16%), 30 of which appeared as microcalcifications.
In 28/268 lesions (10.5%) the biopsy could not be performed (nonidentification of the lesion; inaccessibility due to location or breast size). In 12/240 (5%) biopsies, the sample was not representative. Pathology revealed 100/240 (42%) malignant or borderline lesions and 140/240 (58%) benign lesions. Among the malignant lesions, 16/100 (16%) were invasive carcinoma [infiltrating ductal carcinoma (IDC) or infiltrating lobular carcinoma (ILC)], 13/100 (13%) were microinvasive (T1mic), 35/100 (35%) were ductal carcinoma in situ (DCIS), 9/100 (9%) were lobular carcinoma in situ (CLIS). Among the borderline lesions, 27/100 (27%) were atypical epithelial hyperplasia [atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)]. In 9/100 surgically treated lesions (9%), there was discordance between the microhistological findings of VAB and the pathological results of the surgical procedure: 8/9 were underestimated by VAB (four ADH vs. DCIS, three DCIS vs. IDC, one ADH vs. IDC), and 1/9 was overestimated (T1mic vs. DCIS). Complications following VAB occurred in 9/240 patients (3.7%).
In our experience, VAB showed fair reliability in the diagnosis of nonpalpable breast lesions despite a portion of failed (10.5%), nonsignificant (5%) procedures and underestimated lesions (9%).
根据我们的个人经验评估立体定向真空辅助乳腺活检(VAB)的可靠性。
2003年1月至2005年12月期间,268例患者在我院接受了使用11号探头的VAB检查。纳入标准为乳腺钼靶检查怀疑但超声无法检测到的不可触及病变(微钙化、边界清晰的肿块、结构扭曲),且细针穿刺活检和/或粗针穿刺活检无法明确诊断。病变的乳腺钼靶表现为微钙化186例(77.5%),大多为局限性簇状(130/186:70%);边界清晰的肿块伴或不伴微钙化36例(15%),结构扭曲伴或不伴微钙化18例(7.5%)。根据乳腺影像报告和数据系统(BI-RADS)分类,16例(7%)高度怀疑为恶性(BI-RADS 5级),81例(34%)怀疑为恶性(BI-RADS 4b级),97例(40%)为不明确(BI-RADS 4a级)及46例(19%)可能为良性(BI-RADS 3级)。病变大小≤10mm的有161例(67%),>20mm的仅38例(16%),其中30例表现为微钙化。
28/268例病变(10.5%)无法进行活检(病变未识别;因位置或乳房大小无法到达)。12/240例活检(5%)样本不具代表性。病理显示240例中有100例(42%)为恶性或交界性病变,140例(58%)为良性病变。在恶性病变中,16/100例(16%)为浸润性癌[浸润性导管癌(IDC)或浸润性小叶癌(ILC)],13/100例(13%)为微浸润癌(T1mic),35/100例(35%)为导管原位癌(DCIS),9/100例(9%)为小叶原位癌(CLIS)。在交界性病变中,27/100例(27%)为非典型上皮增生[非典型导管增生(ADH)或非典型小叶增生(ALH)]。9/100例接受手术治疗的病变(9%)中,VAB的微观组织学结果与手术病理结果存在不一致:8/9例被VAB低估(4例ADH误诊为DCIS,3例DCIS误诊为IDC,1例ADH误诊为IDC),1/9例被高估(T1mic误诊为DCIS)。VAB术后并发症发生在第9/240例患者中(3.7%)。
根据我们的经验,尽管部分活检失败(10.5%)、无意义(5%)及病变被低估(9%),VAB在不可触及乳腺病变的诊断中仍显示出一定的可靠性。